Φορτώνει......

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	American Society of Hematology 2014
Θέματα:	Lymphoid Neoplasia
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/ https://ncbi.nlm.nih.gov/pubmed/24829205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

Παρόμοια τεκμήρια